Trials / Unknown
UnknownNCT03503786
Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer
MITO END-3: A Randomized Phase II Trial of Carboplatin+Paclitaxel Compared to Carboplatin+Paclitaxel+Avelumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- National Cancer Institute, Naples · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety and activity of the Avelumab in combination with Carboplatin-Paclitaxel in advanced or recurrent endometrial cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carboplatin | Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles |
| DRUG | Paclitaxel | Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles |
| DRUG | Avelumab | Avelumab 10 mg/kg every 3 weeks for 6-8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity |
Timeline
- Start date
- 2018-04-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2018-04-20
- Last updated
- 2023-11-13
Locations
11 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT03503786. Inclusion in this directory is not an endorsement.